NHS England has reviewed the evidence for the elective discontinuation of immunotherapy in patients who have completed 2 years of therapy.

NHS England has revised its commissioning position such that clinicians and patients will now have the option of discontinuing immunotherapy after 2 or more years of treatment. If such an option is chosen and if there is subsequent disease progression off treatment, NHS will commission the re-start of immunotherapy monotherapy as long as this re-start is the first treatment at that disease relapse.

This follows the news in October 2018 that the previous policy – under which funding would not be available in such circumstances – was to be revised.

Follow this link to download a pdf version of NHS England’s letter which includes an online link to the blueteq registration forms that must be completed by clinicians wishing to offer their patients the option of stopping treatment.